Beam Therapeutics Base Editors Treat Sickle Cell Disease
Summary
Beam Therapeutics Inc. has published US Patent Application US20260108590A1 covering compositions and methods for editing deleterious mutations associated with hemoglobinopathies, including sickle cell disease. The application specifically claims methods for correcting mutations in beta globin polynucleotides using modified adenosine base editors designated "ABE8" achieving efficiency levels exceeding 60-70%. The filing date is October 29, 2025, with publication on April 23, 2026.
“The present invention features compositions and methods for editing deleterious mutations associated with hemoglobinopathies, such as sickle cell disease (SCD).”
About this source
USPTO classification C07K covers peptides: short amino-acid chains that form the backbone of antibodies, hormones, vaccines, and increasingly a wider class of therapeutic modalities. Every newly published application in C07K lands in this feed, around 175 a month. Applications publish 18 months after filing, so this feed reveals what antibody engineering groups, vaccine developers, and plant biotech researchers were working on in the prior year and a half. Watch this if you compete in biologics, file freedom-to-operate analyses on antibody drug candidates, scout acquisition targets in vaccine platforms, or track protein-based agricultural biotech filings.
What changed
Beam Therapeutics Inc. filed US Patent Application US20260108590A1 with the USPTO on October 29, 2025, covering adenosine base editor (ABE8) compositions and methods for correcting beta globin mutations in sickle cell disease and related hemoglobinopathies. The application lists seven named inventors and includes CPC classifications spanning therapeutic compositions (A61K), globin proteins (C07K), and base editor technologies (C12N 9/78, C12N 9/22).
Biopharmaceutical and gene-therapy companies developing genome-editing treatments should monitor this application as it may encumber freedom-to-operate for competing ABE-based sickle cell therapies. The broad claim scope covering both composition-of-matter and method-of-treatment claims in the hemoglobinopathy field represents a potentially significant IP position in the growing base-editing sector.
Archived snapshot
Apr 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
COMPOSITIONS AND METHODS FOR TREATING HEMOGLOBINOPATHIES
Application US20260108590A1 Kind: A1 Apr 23, 2026
Assignee
Beam Therapeutics Inc.
Inventors
Ian Slaymaker, Nicole Gaudelli, Yi Yu, Bernd Zetsche, David A. Born, Seung-Joo Lee, Michael Packer
Abstract
The present invention features compositions and methods for editing deleterious mutations associated with hemoglobinopathies, such as sickle cell disease (SCD). In particular embodiments, the invention provides methods for correcting mutations in a beta globin polynucleotide using modified adenosine base editors termed “ABE8” having unprecedented levels (e.g., >60-70%) of efficiency.
CPC Classifications
A61K 38/50 A61K 31/7088 A61K 35/15 A61K 35/18 A61K 35/28 A61K 38/465 A61P 7/00 A61P 7/06 C07K 14/4717 C12N 5/0641 C12N 9/22 C12N 9/78 C12N 15/11 C12N 15/907 C12Y 305/04004 C07K 2319/09 C12N 2310/20 C12N 2506/11 C12N 2510/00 C12N 2800/80
Filing Date
2025-10-29
Application No.
19372908
Mentioned entities
Parties
Related changes
Get daily alerts for USPTO Patent Applications - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.